|
GWAS dataset
|
Method
|
OR/betaa
|
95% CI
|
P value
|
|---|
|
IGAP AD
|
IVW
|
0.94
|
0.81–1.10
|
4.64E−01
|
|
Weighted median
|
1.02
|
0.83–1.24
|
8.83E−01
|
|
MR-Egger
|
1.09
|
0.85–1.40
|
5.07E−01
|
|
MR-PRESSO
|
0.94
|
0.81–1.10
|
4.71E−01
|
|
UK Biobank AD proxy
|
IVW
|
0.93
|
0.88–0.98
|
1.30E−02
|
|
Weighted median
|
0.92
|
0.87–0.97
|
2.00E−03
|
|
MR-Egger
|
0.91
|
0.84–0.98
|
1.70E−02
|
|
MR-PRESSO
|
0.93
|
0.88–0.98
|
3.41E−02
|
|
Maternal AD group from UK Biobank
|
IVW
|
0.89
|
0.84–0.94
|
8.38E−05
|
|
Weighted median
|
0.87
|
0.82–0.93
|
3.30E−05
|
|
MR-Egger
|
0.86
|
0.80–0.93
|
2.54E−04
|
|
MR-PRESSO
|
0.89
|
0.85–0.93
|
1.05E−03
|
|
Paternal AD group from UK Biobank
|
IVW
|
1.01
|
0.91–1.12
|
8.25E−01
|
|
Weighted median
|
1.00
|
0.92–1.10
|
9.38E−01
|
|
MR-Egger
|
1.00
|
0.87–1.15
|
9.95E−01
|
|
MR-PRESSO
|
1.01
|
0.91–1.12
|
8.30E−01
|
|
Cognitive performance
|
IVW
|
−0.005
|
[−0.034, 0.025]
|
0.754
|
|
Weighted median
|
−0.013
|
[−0.051, 0.025]
|
0.510
|
|
MR-Egger
|
−0.004
|
[−0.054, 0.045]
|
0.865
|
|
MR-PRESSO
|
−0.005
|
[−0.034, 0.025]
|
0.761
|
- OR odds ratio, CI confidence interval, IVW inverse-variance weighted, IGAP International Genomics of Alzheimer’s Project, MR-PRESSO Mendelian randomization pleiotropy residual sum and outlier; the significance of suggestive association between vitamin C levels and AD was at P < 0.05; the significance of statistically significant association between vitamin C levels and AD was at Bonferroni-corrected significance P < 0.05/4 = 0.0125. aOR for AD and AD proxy phenotype, and beta for cognitive performance
